anti sars cov 2 igg elisa  (Immundiagnostik AG)


Bioz Verified Symbol Immundiagnostik AG is a verified supplier
Bioz Manufacturer Symbol Immundiagnostik AG manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 80

    Structured Review

    Immundiagnostik AG anti sars cov 2 igg elisa
    A systematic analysis of vaccine- and infection-induced humoral <t>SARS-CoV-2</t> immune responses in dialysis patients and kidney transplant recipients. ( A ) SARS-CoV-2 surveillance in SARS-CoV-2-naïve dialysis patients. ( B ) Vaccine-induced humoral response in SARS-CoV-2-naïve dialysis patients. ( C ) Booster shot-induced humoral response in SARS-CoV-2 convalescent dialysis patients. ( D ) Vaccine-induced humoral response in SARS-CoV-2-naïve kidney transplant recipients. Vaccines used: BNT162b2 (BioNTech/Pfizer, Mainz, Germany/New York, NY, USA), mRNA-1273 (Moderna, CA, USA), AZD1222 (AstraZeneca/University of Oxford, Cambridge/Oxford, UK). SARS-CoV-2: severe acute respiratory syndrome coronavirus type 2.
    Anti Sars Cov 2 Igg Elisa, supplied by Immundiagnostik AG, used in various techniques. Bioz Stars score: 80/100, based on 3 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti sars cov 2 igg elisa/product/Immundiagnostik AG
    Average 80 stars, based on 3 article reviews
    Price from $9.99 to $1999.99
    anti sars cov 2 igg elisa - by Bioz Stars, 2022-09
    80/100 stars

    Images

    1) Product Images from "Immune Responses to SARS-CoV-2 Infection and Vaccination in Dialysis Patients and Kidney Transplant Recipients"

    Article Title: Immune Responses to SARS-CoV-2 Infection and Vaccination in Dialysis Patients and Kidney Transplant Recipients

    Journal: Microorganisms

    doi: 10.3390/microorganisms10010004

    A systematic analysis of vaccine- and infection-induced humoral SARS-CoV-2 immune responses in dialysis patients and kidney transplant recipients. ( A ) SARS-CoV-2 surveillance in SARS-CoV-2-naïve dialysis patients. ( B ) Vaccine-induced humoral response in SARS-CoV-2-naïve dialysis patients. ( C ) Booster shot-induced humoral response in SARS-CoV-2 convalescent dialysis patients. ( D ) Vaccine-induced humoral response in SARS-CoV-2-naïve kidney transplant recipients. Vaccines used: BNT162b2 (BioNTech/Pfizer, Mainz, Germany/New York, NY, USA), mRNA-1273 (Moderna, CA, USA), AZD1222 (AstraZeneca/University of Oxford, Cambridge/Oxford, UK). SARS-CoV-2: severe acute respiratory syndrome coronavirus type 2.
    Figure Legend Snippet: A systematic analysis of vaccine- and infection-induced humoral SARS-CoV-2 immune responses in dialysis patients and kidney transplant recipients. ( A ) SARS-CoV-2 surveillance in SARS-CoV-2-naïve dialysis patients. ( B ) Vaccine-induced humoral response in SARS-CoV-2-naïve dialysis patients. ( C ) Booster shot-induced humoral response in SARS-CoV-2 convalescent dialysis patients. ( D ) Vaccine-induced humoral response in SARS-CoV-2-naïve kidney transplant recipients. Vaccines used: BNT162b2 (BioNTech/Pfizer, Mainz, Germany/New York, NY, USA), mRNA-1273 (Moderna, CA, USA), AZD1222 (AstraZeneca/University of Oxford, Cambridge/Oxford, UK). SARS-CoV-2: severe acute respiratory syndrome coronavirus type 2.

    Techniques Used: Infection

    Vaccine- and infection-induced humoral response quantified by anti-SARS-CoV-2 IgG titers in dialysis patients compared to vaccinated healthy individuals. ( A ) Vaccine-induced anti-SARS-CoV-2 IgG titers in dialysis patients differ significantly between dialysis patients immunized by BNT162b2, mRNA-1273, and AZD1222 compared to the reference cohort of mRNA-1273 vaccinated healthy individuals. ( B ) Infection induced anti-SARS-CoV-2 IgG titers in convalescent dialysis patients with (w) and without (w/o) booster shot immunization using BNT162b2 mRNA are reduced compared to vaccine-induced titer in healthy individuals. ( C ) Booster shot-induced anti-SARS-CoV-2 IgG titers in SARS-CoV-2-recovered dialysis patients are elevated compared to mRNA vaccine-induced titers in SARS-CoV-2-naïve dialysis patients. Vaccines used: BNT162b2 (BioNTech/Pfizer, Mainz, Germany/New York, NY, USA), mRNA-1273 (Moderna, CA, Unites States), and AZD1222 (AstraZeneca/University of Oxford, Cambridge/Oxford, UK) in dialysis patients; mRNA-1273 (Moderna, CA, Unites States) in healthy individuals. A Kruskal-Wallis test across all groups was used to indicated differences to healthy individuals. Mann–Whitney U test was used to indicated differences between two groups (*** p
    Figure Legend Snippet: Vaccine- and infection-induced humoral response quantified by anti-SARS-CoV-2 IgG titers in dialysis patients compared to vaccinated healthy individuals. ( A ) Vaccine-induced anti-SARS-CoV-2 IgG titers in dialysis patients differ significantly between dialysis patients immunized by BNT162b2, mRNA-1273, and AZD1222 compared to the reference cohort of mRNA-1273 vaccinated healthy individuals. ( B ) Infection induced anti-SARS-CoV-2 IgG titers in convalescent dialysis patients with (w) and without (w/o) booster shot immunization using BNT162b2 mRNA are reduced compared to vaccine-induced titer in healthy individuals. ( C ) Booster shot-induced anti-SARS-CoV-2 IgG titers in SARS-CoV-2-recovered dialysis patients are elevated compared to mRNA vaccine-induced titers in SARS-CoV-2-naïve dialysis patients. Vaccines used: BNT162b2 (BioNTech/Pfizer, Mainz, Germany/New York, NY, USA), mRNA-1273 (Moderna, CA, Unites States), and AZD1222 (AstraZeneca/University of Oxford, Cambridge/Oxford, UK) in dialysis patients; mRNA-1273 (Moderna, CA, Unites States) in healthy individuals. A Kruskal-Wallis test across all groups was used to indicated differences to healthy individuals. Mann–Whitney U test was used to indicated differences between two groups (*** p

    Techniques Used: Infection, MANN-WHITNEY

    Vaccine-induced humoral response quantified by anti-SARS-CoV-2 IgG titers in kidney transplant recipients and healthy individuals. ( A ) Vaccine-induced anti-SARS-CoV-2 IgG titers in kidney transplant recipients are impaired compared to healthy individuals. ( B ) Vaccine-induced anti-SARS-CoV-2 IgG titers are significantly elevated in kidney transplant recipients with immunosuppression lacking mycophenolate mofetil/mycophenolic acid. Vaccines used: BNT162b2 (BioNTech/Pfizer Mainz, Germany/New York, NY, USA) in kidney transplant recipients, and mRNA-1273 (Moderna, CA, United States) in healthy individuals. A Kruskal–Wallis test across all groups was used to indicate differences with respect to healthy individuals. A Mann–Whitney U test was used to indicate differences between two groups (**** p
    Figure Legend Snippet: Vaccine-induced humoral response quantified by anti-SARS-CoV-2 IgG titers in kidney transplant recipients and healthy individuals. ( A ) Vaccine-induced anti-SARS-CoV-2 IgG titers in kidney transplant recipients are impaired compared to healthy individuals. ( B ) Vaccine-induced anti-SARS-CoV-2 IgG titers are significantly elevated in kidney transplant recipients with immunosuppression lacking mycophenolate mofetil/mycophenolic acid. Vaccines used: BNT162b2 (BioNTech/Pfizer Mainz, Germany/New York, NY, USA) in kidney transplant recipients, and mRNA-1273 (Moderna, CA, United States) in healthy individuals. A Kruskal–Wallis test across all groups was used to indicate differences with respect to healthy individuals. A Mann–Whitney U test was used to indicate differences between two groups (**** p

    Techniques Used: MANN-WHITNEY

    2) Product Images from "Evaluation of a new spike (S) protein based commercial immunoassay for the detection of anti-SARS-CoV-2 IgG"

    Article Title: Evaluation of a new spike (S) protein based commercial immunoassay for the detection of anti-SARS-CoV-2 IgG

    Journal: medRxiv

    doi: 10.1101/2021.03.10.21253288

    A) Correlation between five commercial anti-SARS-CoV-2 serological assays and pseudo-virus-neutralizing antibody titer for group B. R represents the Spearman rank correlation coefficient ρ. B) Correlation between five commercial anti-SARS-CoV-2 serological assays and live virus neutralizing antibody titer for group B. Horizontal lines represent cutoff values for individual commercial tests. Kendall’s τ and Cohen’s κ are displayed for each test combination. LVN, live virus neutralization assay; PVN, pseudovirus neutralization assay Specificity of five commercially available serological tests and one virus-neutralizing immunoassay in a SARS-CoV-2 negative control group (group C)
    Figure Legend Snippet: A) Correlation between five commercial anti-SARS-CoV-2 serological assays and pseudo-virus-neutralizing antibody titer for group B. R represents the Spearman rank correlation coefficient ρ. B) Correlation between five commercial anti-SARS-CoV-2 serological assays and live virus neutralizing antibody titer for group B. Horizontal lines represent cutoff values for individual commercial tests. Kendall’s τ and Cohen’s κ are displayed for each test combination. LVN, live virus neutralization assay; PVN, pseudovirus neutralization assay Specificity of five commercially available serological tests and one virus-neutralizing immunoassay in a SARS-CoV-2 negative control group (group C)

    Techniques Used: Neutralization, Negative Control

    A) Correlation between five commercial anti-SARS-CoV-2 serological assays and pseudo-virus-neutralizing antibody titer for group A. R represents the Spearman rank correlation coefficient ρ. B) Correlation between five commercial anti-SARS-CoV-2 serological assays and live virus neutralizing antibody titer for group A. Horizontal lines represent cutoff values for individual commercial tests. Kendall’s τ and Cohen’s κ are displayed for each test combination. LVN, live virus neutralization assay; PVN, pseudovirus neutralization assay Sensitivity of four commercially available serological tests and two virus-neutralizing immunoassays in a cohort of non-responders (group B)
    Figure Legend Snippet: A) Correlation between five commercial anti-SARS-CoV-2 serological assays and pseudo-virus-neutralizing antibody titer for group A. R represents the Spearman rank correlation coefficient ρ. B) Correlation between five commercial anti-SARS-CoV-2 serological assays and live virus neutralizing antibody titer for group A. Horizontal lines represent cutoff values for individual commercial tests. Kendall’s τ and Cohen’s κ are displayed for each test combination. LVN, live virus neutralization assay; PVN, pseudovirus neutralization assay Sensitivity of four commercially available serological tests and two virus-neutralizing immunoassays in a cohort of non-responders (group B)

    Techniques Used: Neutralization

    A) Schematic drawing of the SARS-CoV-2 virus. Spike (S) and nucleocapsid (N) proteins are highlighted. B) Schematic drawing of the trimeric S protein. C) The domain structure of the S protein is shown and the three regions which were tested are depicted. All three versions contain the receptor binding domain (RBD). D) The ELISA procedure is outlined. SP, signal peptide, NTD, N-terminal domain, S1, spike protein subunit 1, S2, spike protein subunit 2, FP, fusion peptide, HR1, heptad repeat 1 domain, HR2, heptad repeat 2 domain, TM, transmembrane domain, FD, foldon motif
    Figure Legend Snippet: A) Schematic drawing of the SARS-CoV-2 virus. Spike (S) and nucleocapsid (N) proteins are highlighted. B) Schematic drawing of the trimeric S protein. C) The domain structure of the S protein is shown and the three regions which were tested are depicted. All three versions contain the receptor binding domain (RBD). D) The ELISA procedure is outlined. SP, signal peptide, NTD, N-terminal domain, S1, spike protein subunit 1, S2, spike protein subunit 2, FP, fusion peptide, HR1, heptad repeat 1 domain, HR2, heptad repeat 2 domain, TM, transmembrane domain, FD, foldon motif

    Techniques Used: Binding Assay, Enzyme-linked Immunosorbent Assay

    3) Product Images from "Evaluation of a new spike (S) protein based commercial immunoassay for the detection of anti-SARS-CoV-2 IgG"

    Article Title: Evaluation of a new spike (S) protein based commercial immunoassay for the detection of anti-SARS-CoV-2 IgG

    Journal: medRxiv

    doi: 10.1101/2021.03.10.21253288

    A) Correlation between five commercial anti-SARS-CoV-2 serological assays and pseudo-virus-neutralizing antibody titer for group B. R represents the Spearman rank correlation coefficient ρ. B) Correlation between five commercial anti-SARS-CoV-2 serological assays and live virus neutralizing antibody titer for group B. Horizontal lines represent cutoff values for individual commercial tests. Kendall’s τ and Cohen’s κ are displayed for each test combination. LVN, live virus neutralization assay; PVN, pseudovirus neutralization assay Specificity of five commercially available serological tests and one virus-neutralizing immunoassay in a SARS-CoV-2 negative control group (group C)
    Figure Legend Snippet: A) Correlation between five commercial anti-SARS-CoV-2 serological assays and pseudo-virus-neutralizing antibody titer for group B. R represents the Spearman rank correlation coefficient ρ. B) Correlation between five commercial anti-SARS-CoV-2 serological assays and live virus neutralizing antibody titer for group B. Horizontal lines represent cutoff values for individual commercial tests. Kendall’s τ and Cohen’s κ are displayed for each test combination. LVN, live virus neutralization assay; PVN, pseudovirus neutralization assay Specificity of five commercially available serological tests and one virus-neutralizing immunoassay in a SARS-CoV-2 negative control group (group C)

    Techniques Used: Neutralization, Negative Control

    A) Correlation between five commercial anti-SARS-CoV-2 serological assays and pseudo-virus-neutralizing antibody titer for group A. R represents the Spearman rank correlation coefficient ρ. B) Correlation between five commercial anti-SARS-CoV-2 serological assays and live virus neutralizing antibody titer for group A. Horizontal lines represent cutoff values for individual commercial tests. Kendall’s τ and Cohen’s κ are displayed for each test combination. LVN, live virus neutralization assay; PVN, pseudovirus neutralization assay Sensitivity of four commercially available serological tests and two virus-neutralizing immunoassays in a cohort of non-responders (group B)
    Figure Legend Snippet: A) Correlation between five commercial anti-SARS-CoV-2 serological assays and pseudo-virus-neutralizing antibody titer for group A. R represents the Spearman rank correlation coefficient ρ. B) Correlation between five commercial anti-SARS-CoV-2 serological assays and live virus neutralizing antibody titer for group A. Horizontal lines represent cutoff values for individual commercial tests. Kendall’s τ and Cohen’s κ are displayed for each test combination. LVN, live virus neutralization assay; PVN, pseudovirus neutralization assay Sensitivity of four commercially available serological tests and two virus-neutralizing immunoassays in a cohort of non-responders (group B)

    Techniques Used: Neutralization

    A) Schematic drawing of the SARS-CoV-2 virus. Spike (S) and nucleocapsid (N) proteins are highlighted. B) Schematic drawing of the trimeric S protein. C) The domain structure of the S protein is shown and the three regions which were tested are depicted. All three versions contain the receptor binding domain (RBD). D) The ELISA procedure is outlined. SP, signal peptide, NTD, N-terminal domain, S1, spike protein subunit 1, S2, spike protein subunit 2, FP, fusion peptide, HR1, heptad repeat 1 domain, HR2, heptad repeat 2 domain, TM, transmembrane domain, FD, foldon motif
    Figure Legend Snippet: A) Schematic drawing of the SARS-CoV-2 virus. Spike (S) and nucleocapsid (N) proteins are highlighted. B) Schematic drawing of the trimeric S protein. C) The domain structure of the S protein is shown and the three regions which were tested are depicted. All three versions contain the receptor binding domain (RBD). D) The ELISA procedure is outlined. SP, signal peptide, NTD, N-terminal domain, S1, spike protein subunit 1, S2, spike protein subunit 2, FP, fusion peptide, HR1, heptad repeat 1 domain, HR2, heptad repeat 2 domain, TM, transmembrane domain, FD, foldon motif

    Techniques Used: Binding Assay, Enzyme-linked Immunosorbent Assay

    Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 80
    Immundiagnostik AG anti sars cov 2 igg elisa
    A systematic analysis of vaccine- and infection-induced humoral <t>SARS-CoV-2</t> immune responses in dialysis patients and kidney transplant recipients. ( A ) SARS-CoV-2 surveillance in SARS-CoV-2-naïve dialysis patients. ( B ) Vaccine-induced humoral response in SARS-CoV-2-naïve dialysis patients. ( C ) Booster shot-induced humoral response in SARS-CoV-2 convalescent dialysis patients. ( D ) Vaccine-induced humoral response in SARS-CoV-2-naïve kidney transplant recipients. Vaccines used: BNT162b2 (BioNTech/Pfizer, Mainz, Germany/New York, NY, USA), mRNA-1273 (Moderna, CA, USA), AZD1222 (AstraZeneca/University of Oxford, Cambridge/Oxford, UK). SARS-CoV-2: severe acute respiratory syndrome coronavirus type 2.
    Anti Sars Cov 2 Igg Elisa, supplied by Immundiagnostik AG, used in various techniques. Bioz Stars score: 80/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti sars cov 2 igg elisa/product/Immundiagnostik AG
    Average 80 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    anti sars cov 2 igg elisa - by Bioz Stars, 2022-09
    80/100 stars
      Buy from Supplier

    88
    Immundiagnostik AG idk anti sars cov 2 s1 igg assay
    ( A ) Schematic drawing of the <t>SARS-CoV-2</t> virus. Spike (S) and nucleocapsid (NC) proteins are highlighted. ( B ) Schematic drawing of the trimeric S-protein. ( C ) The domain structure of the S-protein is shown, and the three regions that were tested are depicted. All three versions contain the receptor binding domain (RBD). SP, signal peptide; NTD, N-terminal domain; S1, spike protein subunit 1; S2, spike protein subunit 2; FP, fusion peptide; HR1, heptad repeat 1 domain; HR2, heptad repeat 2 domain; TM, transmembrane domain; FD, foldon motif.
    Idk Anti Sars Cov 2 S1 Igg Assay, supplied by Immundiagnostik AG, used in various techniques. Bioz Stars score: 88/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/idk anti sars cov 2 s1 igg assay/product/Immundiagnostik AG
    Average 88 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    idk anti sars cov 2 s1 igg assay - by Bioz Stars, 2022-09
    88/100 stars
      Buy from Supplier

    Image Search Results


    A systematic analysis of vaccine- and infection-induced humoral SARS-CoV-2 immune responses in dialysis patients and kidney transplant recipients. ( A ) SARS-CoV-2 surveillance in SARS-CoV-2-naïve dialysis patients. ( B ) Vaccine-induced humoral response in SARS-CoV-2-naïve dialysis patients. ( C ) Booster shot-induced humoral response in SARS-CoV-2 convalescent dialysis patients. ( D ) Vaccine-induced humoral response in SARS-CoV-2-naïve kidney transplant recipients. Vaccines used: BNT162b2 (BioNTech/Pfizer, Mainz, Germany/New York, NY, USA), mRNA-1273 (Moderna, CA, USA), AZD1222 (AstraZeneca/University of Oxford, Cambridge/Oxford, UK). SARS-CoV-2: severe acute respiratory syndrome coronavirus type 2.

    Journal: Microorganisms

    Article Title: Immune Responses to SARS-CoV-2 Infection and Vaccination in Dialysis Patients and Kidney Transplant Recipients

    doi: 10.3390/microorganisms10010004

    Figure Lengend Snippet: A systematic analysis of vaccine- and infection-induced humoral SARS-CoV-2 immune responses in dialysis patients and kidney transplant recipients. ( A ) SARS-CoV-2 surveillance in SARS-CoV-2-naïve dialysis patients. ( B ) Vaccine-induced humoral response in SARS-CoV-2-naïve dialysis patients. ( C ) Booster shot-induced humoral response in SARS-CoV-2 convalescent dialysis patients. ( D ) Vaccine-induced humoral response in SARS-CoV-2-naïve kidney transplant recipients. Vaccines used: BNT162b2 (BioNTech/Pfizer, Mainz, Germany/New York, NY, USA), mRNA-1273 (Moderna, CA, USA), AZD1222 (AstraZeneca/University of Oxford, Cambridge/Oxford, UK). SARS-CoV-2: severe acute respiratory syndrome coronavirus type 2.

    Article Snippet: Anti-SARS-CoV-2 IgG targeting the spike (S) protein was detected by the semiquantitative Euroimmun anti-SARS-CoV-2 IgG ELISA using the Euroimmun Analyzer I (Euroimmun Diagnostik, Lübeck, Germany), and by the quantitative IDK® anti-SARS-CoV-2 IgG ELISA (Immundiagnostik AG, Bensheim, Germany) using the DYNEX DSX® (Dynex Technologies, Chantilly, VA, USA), both using the recombinant S1 antigen of the spike protein, or the chemiluminescent microparticle immunoassay by Abbott for the quantitative detection of anti-spike RBD (receptor binding domain) IgG (SARS-CoV-2 IgG II Quant) using the automated system Alinity i (Abbott, Abbott Park, IL, USA).

    Techniques: Infection

    Vaccine- and infection-induced humoral response quantified by anti-SARS-CoV-2 IgG titers in dialysis patients compared to vaccinated healthy individuals. ( A ) Vaccine-induced anti-SARS-CoV-2 IgG titers in dialysis patients differ significantly between dialysis patients immunized by BNT162b2, mRNA-1273, and AZD1222 compared to the reference cohort of mRNA-1273 vaccinated healthy individuals. ( B ) Infection induced anti-SARS-CoV-2 IgG titers in convalescent dialysis patients with (w) and without (w/o) booster shot immunization using BNT162b2 mRNA are reduced compared to vaccine-induced titer in healthy individuals. ( C ) Booster shot-induced anti-SARS-CoV-2 IgG titers in SARS-CoV-2-recovered dialysis patients are elevated compared to mRNA vaccine-induced titers in SARS-CoV-2-naïve dialysis patients. Vaccines used: BNT162b2 (BioNTech/Pfizer, Mainz, Germany/New York, NY, USA), mRNA-1273 (Moderna, CA, Unites States), and AZD1222 (AstraZeneca/University of Oxford, Cambridge/Oxford, UK) in dialysis patients; mRNA-1273 (Moderna, CA, Unites States) in healthy individuals. A Kruskal-Wallis test across all groups was used to indicated differences to healthy individuals. Mann–Whitney U test was used to indicated differences between two groups (*** p

    Journal: Microorganisms

    Article Title: Immune Responses to SARS-CoV-2 Infection and Vaccination in Dialysis Patients and Kidney Transplant Recipients

    doi: 10.3390/microorganisms10010004

    Figure Lengend Snippet: Vaccine- and infection-induced humoral response quantified by anti-SARS-CoV-2 IgG titers in dialysis patients compared to vaccinated healthy individuals. ( A ) Vaccine-induced anti-SARS-CoV-2 IgG titers in dialysis patients differ significantly between dialysis patients immunized by BNT162b2, mRNA-1273, and AZD1222 compared to the reference cohort of mRNA-1273 vaccinated healthy individuals. ( B ) Infection induced anti-SARS-CoV-2 IgG titers in convalescent dialysis patients with (w) and without (w/o) booster shot immunization using BNT162b2 mRNA are reduced compared to vaccine-induced titer in healthy individuals. ( C ) Booster shot-induced anti-SARS-CoV-2 IgG titers in SARS-CoV-2-recovered dialysis patients are elevated compared to mRNA vaccine-induced titers in SARS-CoV-2-naïve dialysis patients. Vaccines used: BNT162b2 (BioNTech/Pfizer, Mainz, Germany/New York, NY, USA), mRNA-1273 (Moderna, CA, Unites States), and AZD1222 (AstraZeneca/University of Oxford, Cambridge/Oxford, UK) in dialysis patients; mRNA-1273 (Moderna, CA, Unites States) in healthy individuals. A Kruskal-Wallis test across all groups was used to indicated differences to healthy individuals. Mann–Whitney U test was used to indicated differences between two groups (*** p

    Article Snippet: Anti-SARS-CoV-2 IgG targeting the spike (S) protein was detected by the semiquantitative Euroimmun anti-SARS-CoV-2 IgG ELISA using the Euroimmun Analyzer I (Euroimmun Diagnostik, Lübeck, Germany), and by the quantitative IDK® anti-SARS-CoV-2 IgG ELISA (Immundiagnostik AG, Bensheim, Germany) using the DYNEX DSX® (Dynex Technologies, Chantilly, VA, USA), both using the recombinant S1 antigen of the spike protein, or the chemiluminescent microparticle immunoassay by Abbott for the quantitative detection of anti-spike RBD (receptor binding domain) IgG (SARS-CoV-2 IgG II Quant) using the automated system Alinity i (Abbott, Abbott Park, IL, USA).

    Techniques: Infection, MANN-WHITNEY

    Vaccine-induced humoral response quantified by anti-SARS-CoV-2 IgG titers in kidney transplant recipients and healthy individuals. ( A ) Vaccine-induced anti-SARS-CoV-2 IgG titers in kidney transplant recipients are impaired compared to healthy individuals. ( B ) Vaccine-induced anti-SARS-CoV-2 IgG titers are significantly elevated in kidney transplant recipients with immunosuppression lacking mycophenolate mofetil/mycophenolic acid. Vaccines used: BNT162b2 (BioNTech/Pfizer Mainz, Germany/New York, NY, USA) in kidney transplant recipients, and mRNA-1273 (Moderna, CA, United States) in healthy individuals. A Kruskal–Wallis test across all groups was used to indicate differences with respect to healthy individuals. A Mann–Whitney U test was used to indicate differences between two groups (**** p

    Journal: Microorganisms

    Article Title: Immune Responses to SARS-CoV-2 Infection and Vaccination in Dialysis Patients and Kidney Transplant Recipients

    doi: 10.3390/microorganisms10010004

    Figure Lengend Snippet: Vaccine-induced humoral response quantified by anti-SARS-CoV-2 IgG titers in kidney transplant recipients and healthy individuals. ( A ) Vaccine-induced anti-SARS-CoV-2 IgG titers in kidney transplant recipients are impaired compared to healthy individuals. ( B ) Vaccine-induced anti-SARS-CoV-2 IgG titers are significantly elevated in kidney transplant recipients with immunosuppression lacking mycophenolate mofetil/mycophenolic acid. Vaccines used: BNT162b2 (BioNTech/Pfizer Mainz, Germany/New York, NY, USA) in kidney transplant recipients, and mRNA-1273 (Moderna, CA, United States) in healthy individuals. A Kruskal–Wallis test across all groups was used to indicate differences with respect to healthy individuals. A Mann–Whitney U test was used to indicate differences between two groups (**** p

    Article Snippet: Anti-SARS-CoV-2 IgG targeting the spike (S) protein was detected by the semiquantitative Euroimmun anti-SARS-CoV-2 IgG ELISA using the Euroimmun Analyzer I (Euroimmun Diagnostik, Lübeck, Germany), and by the quantitative IDK® anti-SARS-CoV-2 IgG ELISA (Immundiagnostik AG, Bensheim, Germany) using the DYNEX DSX® (Dynex Technologies, Chantilly, VA, USA), both using the recombinant S1 antigen of the spike protein, or the chemiluminescent microparticle immunoassay by Abbott for the quantitative detection of anti-spike RBD (receptor binding domain) IgG (SARS-CoV-2 IgG II Quant) using the automated system Alinity i (Abbott, Abbott Park, IL, USA).

    Techniques: MANN-WHITNEY

    A) Correlation between five commercial anti-SARS-CoV-2 serological assays and pseudo-virus-neutralizing antibody titer for group B. R represents the Spearman rank correlation coefficient ρ. B) Correlation between five commercial anti-SARS-CoV-2 serological assays and live virus neutralizing antibody titer for group B. Horizontal lines represent cutoff values for individual commercial tests. Kendall’s τ and Cohen’s κ are displayed for each test combination. LVN, live virus neutralization assay; PVN, pseudovirus neutralization assay Specificity of five commercially available serological tests and one virus-neutralizing immunoassay in a SARS-CoV-2 negative control group (group C)

    Journal: medRxiv

    Article Title: Evaluation of a new spike (S) protein based commercial immunoassay for the detection of anti-SARS-CoV-2 IgG

    doi: 10.1101/2021.03.10.21253288

    Figure Lengend Snippet: A) Correlation between five commercial anti-SARS-CoV-2 serological assays and pseudo-virus-neutralizing antibody titer for group B. R represents the Spearman rank correlation coefficient ρ. B) Correlation between five commercial anti-SARS-CoV-2 serological assays and live virus neutralizing antibody titer for group B. Horizontal lines represent cutoff values for individual commercial tests. Kendall’s τ and Cohen’s κ are displayed for each test combination. LVN, live virus neutralization assay; PVN, pseudovirus neutralization assay Specificity of five commercially available serological tests and one virus-neutralizing immunoassay in a SARS-CoV-2 negative control group (group C)

    Article Snippet: Conflicts of InterestThe University of Cologne (Medical Faculty) receives royalties for the co-development of the IDK® anti-SARS-CoV-2 IgG ELISA and IDK® anti-SARS-CoV-2 IgM ELISA kits.

    Techniques: Neutralization, Negative Control

    A) Correlation between five commercial anti-SARS-CoV-2 serological assays and pseudo-virus-neutralizing antibody titer for group A. R represents the Spearman rank correlation coefficient ρ. B) Correlation between five commercial anti-SARS-CoV-2 serological assays and live virus neutralizing antibody titer for group A. Horizontal lines represent cutoff values for individual commercial tests. Kendall’s τ and Cohen’s κ are displayed for each test combination. LVN, live virus neutralization assay; PVN, pseudovirus neutralization assay Sensitivity of four commercially available serological tests and two virus-neutralizing immunoassays in a cohort of non-responders (group B)

    Journal: medRxiv

    Article Title: Evaluation of a new spike (S) protein based commercial immunoassay for the detection of anti-SARS-CoV-2 IgG

    doi: 10.1101/2021.03.10.21253288

    Figure Lengend Snippet: A) Correlation between five commercial anti-SARS-CoV-2 serological assays and pseudo-virus-neutralizing antibody titer for group A. R represents the Spearman rank correlation coefficient ρ. B) Correlation between five commercial anti-SARS-CoV-2 serological assays and live virus neutralizing antibody titer for group A. Horizontal lines represent cutoff values for individual commercial tests. Kendall’s τ and Cohen’s κ are displayed for each test combination. LVN, live virus neutralization assay; PVN, pseudovirus neutralization assay Sensitivity of four commercially available serological tests and two virus-neutralizing immunoassays in a cohort of non-responders (group B)

    Article Snippet: Conflicts of InterestThe University of Cologne (Medical Faculty) receives royalties for the co-development of the IDK® anti-SARS-CoV-2 IgG ELISA and IDK® anti-SARS-CoV-2 IgM ELISA kits.

    Techniques: Neutralization

    A) Schematic drawing of the SARS-CoV-2 virus. Spike (S) and nucleocapsid (N) proteins are highlighted. B) Schematic drawing of the trimeric S protein. C) The domain structure of the S protein is shown and the three regions which were tested are depicted. All three versions contain the receptor binding domain (RBD). D) The ELISA procedure is outlined. SP, signal peptide, NTD, N-terminal domain, S1, spike protein subunit 1, S2, spike protein subunit 2, FP, fusion peptide, HR1, heptad repeat 1 domain, HR2, heptad repeat 2 domain, TM, transmembrane domain, FD, foldon motif

    Journal: medRxiv

    Article Title: Evaluation of a new spike (S) protein based commercial immunoassay for the detection of anti-SARS-CoV-2 IgG

    doi: 10.1101/2021.03.10.21253288

    Figure Lengend Snippet: A) Schematic drawing of the SARS-CoV-2 virus. Spike (S) and nucleocapsid (N) proteins are highlighted. B) Schematic drawing of the trimeric S protein. C) The domain structure of the S protein is shown and the three regions which were tested are depicted. All three versions contain the receptor binding domain (RBD). D) The ELISA procedure is outlined. SP, signal peptide, NTD, N-terminal domain, S1, spike protein subunit 1, S2, spike protein subunit 2, FP, fusion peptide, HR1, heptad repeat 1 domain, HR2, heptad repeat 2 domain, TM, transmembrane domain, FD, foldon motif

    Article Snippet: Conflicts of InterestThe University of Cologne (Medical Faculty) receives royalties for the co-development of the IDK® anti-SARS-CoV-2 IgG ELISA and IDK® anti-SARS-CoV-2 IgM ELISA kits.

    Techniques: Binding Assay, Enzyme-linked Immunosorbent Assay

    ( A ) Schematic drawing of the SARS-CoV-2 virus. Spike (S) and nucleocapsid (NC) proteins are highlighted. ( B ) Schematic drawing of the trimeric S-protein. ( C ) The domain structure of the S-protein is shown, and the three regions that were tested are depicted. All three versions contain the receptor binding domain (RBD). SP, signal peptide; NTD, N-terminal domain; S1, spike protein subunit 1; S2, spike protein subunit 2; FP, fusion peptide; HR1, heptad repeat 1 domain; HR2, heptad repeat 2 domain; TM, transmembrane domain; FD, foldon motif.

    Journal: Microorganisms

    Article Title: Evaluation of a New Spike (S)-Protein-Based Commercial Immunoassay for the Detection of Anti-SARS-CoV-2 IgG

    doi: 10.3390/microorganisms9040733

    Figure Lengend Snippet: ( A ) Schematic drawing of the SARS-CoV-2 virus. Spike (S) and nucleocapsid (NC) proteins are highlighted. ( B ) Schematic drawing of the trimeric S-protein. ( C ) The domain structure of the S-protein is shown, and the three regions that were tested are depicted. All three versions contain the receptor binding domain (RBD). SP, signal peptide; NTD, N-terminal domain; S1, spike protein subunit 1; S2, spike protein subunit 2; FP, fusion peptide; HR1, heptad repeat 1 domain; HR2, heptad repeat 2 domain; TM, transmembrane domain; FD, foldon motif.

    Article Snippet: Sensitivity of Immundiagnostik IDK® Anti-SARS-CoV-2 S1 IgG Assay and Three Commercially Available Serological Tests in a Cohort of COVID-19 Convalescent Subjects That Were Primarily Tested S1 IgG Non-Reactive (Group B)Between April and July 2020, 169 individuals with confirmed prior SARS-CoV-2 infection attending our clinic were classified as non-reactive in the routine IgG screening using the Euroimmun S1 IgG ELISA (group B).

    Techniques: Binding Assay

    ( A ) Correlation between five commercial anti-SARS-CoV-2 serological assays and a pseudovirus neutralizing antibody titer for group A. R represents the Spearman rank correlation coefficient ρ. ( B ) Correlation between five commercial anti-SARS-CoV-2 serological assays and live virus neutralizing antibody titer for group A. Horizontal lines represent cutoff values for individual commercial tests. Kendall’s τ and Cohen’s κ are displayed for each test combination. LVN, live virus neutralization assay; PVN, pseudovirus neutralization assay; ID100, 100% inhibitory dilution; ID50, 50% inhibitory dose.

    Journal: Microorganisms

    Article Title: Evaluation of a New Spike (S)-Protein-Based Commercial Immunoassay for the Detection of Anti-SARS-CoV-2 IgG

    doi: 10.3390/microorganisms9040733

    Figure Lengend Snippet: ( A ) Correlation between five commercial anti-SARS-CoV-2 serological assays and a pseudovirus neutralizing antibody titer for group A. R represents the Spearman rank correlation coefficient ρ. ( B ) Correlation between five commercial anti-SARS-CoV-2 serological assays and live virus neutralizing antibody titer for group A. Horizontal lines represent cutoff values for individual commercial tests. Kendall’s τ and Cohen’s κ are displayed for each test combination. LVN, live virus neutralization assay; PVN, pseudovirus neutralization assay; ID100, 100% inhibitory dilution; ID50, 50% inhibitory dose.

    Article Snippet: Sensitivity of Immundiagnostik IDK® Anti-SARS-CoV-2 S1 IgG Assay and Three Commercially Available Serological Tests in a Cohort of COVID-19 Convalescent Subjects That Were Primarily Tested S1 IgG Non-Reactive (Group B)Between April and July 2020, 169 individuals with confirmed prior SARS-CoV-2 infection attending our clinic were classified as non-reactive in the routine IgG screening using the Euroimmun S1 IgG ELISA (group B).

    Techniques: Neutralization

    ( A ) Correlation between five commercial anti-SARS-CoV-2 serological assays and the pseudovirus neutralizing antibody titer for group B. R represents the Spearman rank correlation coefficient ρ. ( B ) Correlation between five commercial anti-SARS-CoV-2 serological assays and live virus neutralizing antibody titer for group B. Horizontal lines represent cutoff values for individual commercial tests. Kendall’s τ and Cohen’s κ are displayed for each test combination. LVN, live virus neutralization assay; PVN, pseudovirus neutralization assay; ID100, 100% inhibitory dilution; ID50, 50% inhibitory dose.

    Journal: Microorganisms

    Article Title: Evaluation of a New Spike (S)-Protein-Based Commercial Immunoassay for the Detection of Anti-SARS-CoV-2 IgG

    doi: 10.3390/microorganisms9040733

    Figure Lengend Snippet: ( A ) Correlation between five commercial anti-SARS-CoV-2 serological assays and the pseudovirus neutralizing antibody titer for group B. R represents the Spearman rank correlation coefficient ρ. ( B ) Correlation between five commercial anti-SARS-CoV-2 serological assays and live virus neutralizing antibody titer for group B. Horizontal lines represent cutoff values for individual commercial tests. Kendall’s τ and Cohen’s κ are displayed for each test combination. LVN, live virus neutralization assay; PVN, pseudovirus neutralization assay; ID100, 100% inhibitory dilution; ID50, 50% inhibitory dose.

    Article Snippet: Sensitivity of Immundiagnostik IDK® Anti-SARS-CoV-2 S1 IgG Assay and Three Commercially Available Serological Tests in a Cohort of COVID-19 Convalescent Subjects That Were Primarily Tested S1 IgG Non-Reactive (Group B)Between April and July 2020, 169 individuals with confirmed prior SARS-CoV-2 infection attending our clinic were classified as non-reactive in the routine IgG screening using the Euroimmun S1 IgG ELISA (group B).

    Techniques: Neutralization